Comparative safety of antiretroviral treatment regimens in pregnancy

JAMA Pediatrics

Volumn 171, Issue 10, 2017, Pages

  Zash, Rebecca ^a   Jacobson, Denise L ^b   Diseko, Modiegi ^c   Mayondi, Gloria ^c   Mmalane, Mompati ^c   Essex, Max ^d   Petlo, Chipo ^e   Lockman, Shahin ^f   Makhema, Joseph ^c   Shapiro, Roger L ^d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e Department of HIV AIDS Prevention and Care   (Botswana)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE;

ADULT; ADVERSE OUTCOME; ANTIRETROVIRAL THERAPY; ARTICLE; CLINICAL OUTCOME; CONCEPTION; DRUG SAFETY; FEMALE; GESTATIONAL AGE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVE BIRTH; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; NEWBORN DEATH; OBSERVATIONAL STUDY; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SMALL FOR DATE INFANT; STILLBIRTH; STUDY; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; EPIDEMIOLOGY; HIV INFECTIONS; PREGNANCY; PRENATAL EXPOSURE; RISK ASSESSMENT;

ADULT; ANTI-RETROVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT;

EID: 85030776013     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2017.2222     Document Type: Article

References (39)

1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization Programme, Geneva, Switzerland. http://www.who.int/hiv/pub/arv/arv-2016/en/. June 2016. Accessed January 2, 2017.
2. UNICEF. For every child, end AIDS: seventh stocktaking report, 2016. http://st7.childrenandaids.org/sites/default/files/STR%202016%20Report %2012_9%20LR_.pdf. December 2016. Accessed January 2, 2016.
3. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206(11):1695-1705.
4. Zash R, Souda S, Chen JY, et al. Reassuring birth outcomes with tenofovir/emtricitabine/efavirenz used for prevention of mother-to-child transmission of HIV in Botswana. J Acquir Immune Defic Syndr. 2016;71(4):428-436.
5. Fowler MG, Qin M, Fiscus SA, et al; IMPAACT 1077BF/1077FF PROMISE Study Team. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375(18):1726-1737.
6. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis. 2012;54(9): 1348-1360.
7. Uthman OA, Nachega JB, Anderson J, et al. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. Lancet HIV. 2017;4(1):e21-e30.
8. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21(8): 1019-1026.
9. Cotter AM, Garcia AG, Duthely ML, Luke B, O’Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193(9):1195-1201.
10. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204(4):506-514.
11. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18(17):2337-2339.
12. Ravizza M, Martinelli P, Bucceri A, et al; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis. 2007; 195(6):913-914.
13. Fiore S, Ferrazzi E, Newell ML, Trabattoni D, Clerici M. Protease inhibitor–associated increased risk of preterm delivery is an immunological complication of therapy. J Infect Dis. 2007;195(6): 914-916.
14. Ouattara EN, Anglaret X, Wong AY, et al. Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. AIDS. 2012; 26(5):625-634.
15. Bussmann H, Wester CW, Wester CN, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J Acquir Immune Defic Syndr. 2007;45(3):269-273.
16. Ekouevi DK, Coffie PA, Ouattara E, et al; International Epidemiological Database to Evaluate AIDS West Africa; ANRS 1269 and ANRS 12136 Study Groups in Abidjan. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS databases, Abidjan, Côte d’Ivoire. J Acquir Immune Defic Syndr. 2011;56(2):183-187.
17. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25(18):2301-2304.
18. Li N, Sando MM, Spiegelman D, et al. Antiretroviral therapy in relation to birth outcomes among HIV-infected women: a cohort study. J Infect Dis. 2016;213(7):1057-1064.
19. UNAIDS. HIV and AIDS estimates (2015). http://www.unaids.org/en/regionscountries/countries/botswana. 2015. Accessed January 2, 2017.
20. World Health Organization. Botswana: WHO statistical profile. http://www.who.int/gho/countries/bwa.pdf?ua=1&ua=1. Updated January 2015. Accessed January 2, 2017.
21. National AIDS Coordinating Agency. Progress report of the national response to the 2011 declaration of commitments on HIV and AIDS. http://www.unaids.org/sites/default/files/country /documents/BWA_narrative_report_2015.pdf. June 2015. Accessed January 2, 2017.
22. Ministry of Health and Wellness. Botswana National HIV & AIDS Treatment Guidelines. 2012 Version. http://www.moh.gov.bw. April 1, 2012. Accessed December 7, 2016.
23. Republic of Botswana. Health Statistics Report 2009. http://www.statsbots.org.bw/sites/default/files/publications/Health%2520Statistics %2520Annual%2520Report_2009%5B2%5D.pdf. December 2012. Accessed January 2, 2017.
24. Republic of Botswana. Handbook of the Botswana 2016 Integrated HIV Clinical Care Guidelines. http://apps.who.int/medicinedocs/documents/s22413en/s22413en.pdf. Accessed January 2, 2017.
25. Villar J, Cheikh Ismail L, Victora CG, et al; International Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st). International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet. 2014;384(9946):857-868.
26. Villar J, Giuliani F, Fenton TR, Ohuma EO, Ismail LC, Kennedy SH; INTERGROWTH-21st Consortium. INTERGROWTH-21st very preterm size at birth reference charts. Lancet. 2016;387(10021): 844-845.
27. Interagency Task Team. 2015 IATT Annual Report. http://www.emtct-iatt.org/wp-content/uploads/2016/08/IATT-2015-Annual-Report.pdf. February 26, 2015. Accessed June 26, 2017.
28. Rollins NC, Coovadia HM, Bland RM, et al. Pregnancy outcomes in HIV-infected and uninfected women in rural and urban South Africa. J Acquir Immune Defic Syndr. 2007;44(3):321-328.
29. Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect. 2009; 85(2):82-87.
30. Shapiro RL, Souda S, Parekh N, et al. High prevalence of hypertension and placental insufficiency, but no in utero HIV transmission, among women on HAART with stillbirths in Botswana. PLoS One. 2012;7(2):e31580.
31. O’Halloran JA, Dunne E, Gurwith M, et al. The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection. HIV Med. 2015;16(10):608-619.
32. Blodget E, Shen C, Aldrovandi G, et al. Relationship between microbial translocation and endothelial function in HIV infected patients. PLoS One. 2012;7(8):e42624.
33. Fiore S, Newell ML, Trabattoni D, et al. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol. 2006;70(1-2): 143-150.
34. Papp E, Mohammadi H, Loutfy MR, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis. 2015;211(1): 10-18.
35. Shaffer D, Hughes MD, Sawe F, et al. Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in sub-Saharan Africa: A5208 (OCTANE). J Acquir Immune Defic Syndr. 2014;66(2):155-163.
36. Germain AM, Romanik MC, Guerra I, et al. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension. 2007;49(1): 90-95.
37. Lawn JE, Blencowe H, Waiswa P, et al; Lancet Ending Preventable Stillbirths Series Study Group; Lancet Stillbirth Epidemiology Investigator Group. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet. 2016;387(10018):587-603.
38. Lawn JE, Cousens S, Zupan J; Lancet Neonatal Survival Steering Team. 4 Million neonatal deaths: when? where? why? Lancet. 2005;365(9462): 891-900.
39. Shapiro R, Dryden-Peterson S, Powis K, Zash R, Lockman S. Hidden in plain sight: HIV, antiretrovirals, and stillbirths. Lancet. 2016;387 (10032):1994-1995.